Status:
COMPLETED
Effects of Vildagliptine and Glimepiride on Glucose Variability
Lead Sponsor:
Seoul National University Hospital
Conditions:
Diabetes Mellitus, Non-Insulin-Dependent
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to analyze the differences of blood sugar level and glycemic variability between sulfonylurea and DPP-4 inhibitor groups applying CGMS for a chosen number of type 2 DM pat...
Detailed Description
We enroll patients with type 2 DM with uncontrolled glucose level on Metformin monotherapy over 1000mg /day (HbA1C over 7%). Before drug administration, we conduct basal lab study including CGMS. Aft...
Eligibility Criteria
Inclusion
- with type 2 DM
- with uncontrolled glucose level on Metformin monotherapy over 1000mg /day (HbA1C over 7%). Provided that the tolerance for metformin is poor, enrollment of patients with lower dose of metfomrin is open.
- who have never been prescribed with test drugs, sulfonylurea or DPP-4 inhibitor/GLP-1 analogue in 3 months
- who can be applied with CGMS
Exclusion
- who has liver function abnormality or renal function abnormality
- who has any kind of diseases, operations, medical treatments that can affect glucose levels
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01812122
Start Date
March 1 2013
End Date
October 1 2015
Last Update
November 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744